Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Slides:

Advertisements

Similar presentations

Peritoneal transport assessment by peritoneal equilibration test with 3.86% glucose: A long-term prospective evaluation V. La Milia, P. Pozzoni, G. Virga,

Advertisements

Volume 54, Pages S135-S139 (December 1998)

Management of IgA nephropathy: Evidence-based recommendations

Isolated Systolic Hypertension: An Update After SPRINT

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Viper venom for diabetic nephropathy

Volume 56, Pages S95-S98 (November 1999)

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation Anil K. Bidani, M.D., Karen A. Griffin,

Step Care Therapy for Hypertension in Diabetic Patients

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Progression of renal failure and hypertensive nephrosclerosis

Volume 53, Issue 4, Pages (April 1998)

Volume 65, Issue 6, Pages (June 2004)

Francesco Paolo Schena Kidney International

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Volume 80, Issue 9, Pages (November 2011)

Volume 94, Issue 3, Pages (September 2018)

Volume 70, Pages S21-S25 (December 2006)

Volume 57, Pages S32-S37 (April 2000)

Comorbidity and confounding in end-stage renal disease

A new era in phosphate binder therapy: What are the options?

Steven J. Rosansky, Richard J. Glassock Kidney International

Volume 70, Issue 11, Pages (December 2006)

Hypertension After Kidney Transplant

Patient selection affects end-stage renal disease outcome comparisons

Volume 72, Issue 12, Pages (December 2007)

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Study of Heart and Renal Protection (SHARP)

Saulo Klahr, Jeremiah J. Morrissey Kidney International

Blood pressure targets in hemodialysis patients

Volume 72, Issue 12, Pages (December 2007)

Volume 69, Issue 12, Pages (June 2006)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Volume 68, Issue 2, Pages (August 2005)

Volume 67, Issue 1, Pages (January 2005)

Francesco Locatelli, Lucia Del Vecchio Kidney International

The future of renoprotection: Frustration and promises

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

AGEs in foods: Do they play a role in uremia?

Volume 87, Issue 1, Pages (January 2015)

The kidney, a cardiovascular risk marker, and a new target for therapy

Volume 67, Pages S52-S54 (January 2005)

Counteracting progression of renal disease: A look into the future

Isolated Systolic Hypertension: An Update After SPRINT

Volume 54, Pages S135-S139 (December 1998)

Volume 62, Pages S47-S52 (December 2002)

Volume 67, Pages S15-S19 (January 2005)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

The course of the remnant kidney model in mice

Volume 73, Issue 5, Pages (March 2008)

Volume 53, Issue 6, Pages (June 1998)

Clinical benefits of slowing the progression of renal failure

This Month in AJKD American Journal of Kidney Diseases

Volume 68, Pages S98-S102 (December 2005)

Is it the low-protein diet or simply the salt restriction?

Volume 64, Issue 4, Pages (October 2003)

Charles A. Herzog Kidney International

Volume 75, Issue 1, Pages (January 2009)

Volume 62, Pages S68-S72 (December 2002)

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications

Evaluation of the Losartan in Hemodialysis (ELHE) Study

Volume 58, Issue 5, Pages (November 2000)

Kidney and hypertension

Proteinuria and hypertension with tyrosine kinase inhibitors

Antonio Piccoli, Luana Pillon Kidney International

Volume 64, Pages S131-S136 (November 2003)

Presentation transcript:

Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani Kidney International Volume 62, Pages S53-S60 (December 2002) DOI: 10.1046/j.1523-1755.62.s82.11.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Relationship between systolic blood pressure achieved during follow-up and proteinuria levels in the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency (AIPRI) study14. Proteinuria is directly related to systolic blood pressure, but patients treated with ACEIs have lower proteinuria levels than those treated with placebo even at lower systolic blood pressure values. Symbols are: (□, dotted line) benazepril group; (○, solid line) placebo group. Kidney International 2002 62, S53-S60DOI: (10.1046/j.1523-1755.62.s82.11.x) Copyright © 2002 International Society of Nephrology Terms and Conditions